Shenzhen Salubris Pharmaceuticals Co: Patented and new product growth offset generic drug declines, keeping Q1 profit stable

About this update from Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

Q1 2025 revenue declined 2.64% year-over-year to RMB 1.06 billion, with net profit stable at RMB 200 million as growth in patented and new products offset generic drug declines. Operating cash flow fell 26.39% amid higher R&D and promotion spending.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A